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ABSTRACT 
Colorectal cancer is an important public health problem which fulfills the characteristics of 
the World Health Organization for population-based screening. The Health Provider 
System (Servicio Navarro de Salud) has started to implement this screening through a Fecal 
Occult Blood Test (FOBT). The overview of the literature concludes that this type of test 
is cost-effective under the threshold of 30,000 €/QALY for efficiency and so is the cost-
utility analysis. In the case of Navarra, the economic analysis has also proved that the 
FOBT is cost-effective. This screening program also provides health benefits and a 
reduction in the incidence and mortality rate of colorectal cancer which has become 
increasingly important as the mortality rate has risen.  
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1. INTRODUCTION 
Nowadays, colorectal cancer (CRC) is one of the most important health problems in the 
developed countries due to its high incidence and mortality rates. In Spain, around 19,000 
new cases are diagnosed annually, ranking first in incidence and second in cancer mortality 
(Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012). In Navarra, 
colorectal cancer ranks third in incidence in men and second in women; and is the second 
leading cause of overall cancer deaths in men (130 died in 2010 after lung) and first in 
women (75 in 2010). The mortality ratio has caught up to the breast cancer in women, 
which incidence has fallen by the existence of the program of early detection of breast 
cancer. 
The colorectal cancer screening is a population-based program which aims to reduce the 
incidence and mortality from colorectal cancer, because in recent years it has experienced 
an increase in incidence. This change can be explained due to the increase in life 
expectancy and changes in lifestyle (diet, sedentary lifestyle, obesity). Therefore, the 
program of early detection of colorectal cancer is focused on the reduction of incidence 
and mortality and, it has been proved in other countries that there is an improvement in 
the quality of life of the patients who have had an early diagnose. This program has been 
implemented in 19 member states of the European Union and in some autonomous 
communities inside Spain. This program is worldwide implemented. Canada, Australia, 
Japan or United States are examples besides these European countries. 
A report published in 2008 about the recommendations of colorectal cancer screening in 
the European Union, concludes that 19 of the 28 member states already have implemented 
(or are implementing) screening programs for colorectal cancer. 12 of them are population-
based (Cyprus, Finland, France, Hungary, Italy, Poland, Portugal, Romania, Slovenia, Spain, 
Sweden and the UK). 7 are programs that are not population based (Austria, Bulgaria, the 
Czech Republic, Germany, Greece, Latvia and the Slovak Republic) (Programa de 
Detección Precoz de Cáncer Colorectal de Navarra, 2012). 
According to the latest report of the Spanish Screening Network (Red de Programas 
Españoles de Cribado), 14 regions out of the 17 have realized in 2012 a colorectal cancer 
screening program. 9 are already developing CRC screening programs (Aragon, Valencia 
Community, Canarias, Cantabria, Catalonia, Castilla-Leon, Murcia, the Basque Country and 
La Rioja). Catalonia was the first to initiate this activity in 2000 (Programa de Detección 
Precoz de Cáncer Colorectal de Navarra, 2012).  
6 
 
Nowadays, if colorectal cancer is diagnosed on time, the disease can be healed in 90% of 
the cases. However, the percentage drops below 50% if detected at advanced stages 
(Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012). 
In Navarra, the colorectal cancer screening is population-based. The target people are 
women and men between 50-69 years old (population at average risk of developing the 
disease, around 160,000 inhabitants in Navarra). This implies that the target is the 24% of 
the population of Navarra (Programa de Detección Precoz de Cáncer Colorectal de 
Navarra, 2012). 
Screening for colorectal cancer has been proved in the literature to be cost-effective 
(Telford MD, et al., 2010; Lansdorp-Vogelaar, et al., 2010; Heitman, et al., 2010; Tran, et 
al., 2010; Jeong, et al., 2013). So, the key point for the Health Service Provider is the 
coordination with other health or non-health groups that can collaborate in promoting the 
participation of the screening (pharmacies, municipalities, mutual aid groups, neighborhood 
associations, associations…), leading to a higher percentage of the participation of the 
population targeted.  
Along this report, an analysis of costs and effectiveness of the program in Navarra is 
presented. The program consists of a screening test for Fecal Occult Blood offered to all 
population between 50 and 69 years. 
Implementing this screening increases the welfare of the people being tested because if the 
disease is detected early, it can dramatically change the course of the illness. And the cure 
rate can also increase. Moreover, an appealing fact to do this screening is that a 
colonoscopy (a further test of the screening) can detect polyps. These precursor lesions can 
be removed and can prevent the cancer cycle from beginning in the first place. 
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2. COLORECTAL CANCER 
2.1. Colorectal cancer: definition and types 
As the American Cancer Society defines, the colorectal cancer is a cancer that begins in 
either the colon or the rectum (Colorectal Cancer, 2014).  
Cancer cell growth is different from normal cell growth. Instead of dying, cancer cells 
continue to grow and form new and abnormal cells. Cancer cells can also invade other 
tissues, something that normal cells cannot do. Growing out of control and invading other 
tissues are what makes a cell to become cancerous. 
 
2.1.1. Abnormal growths in the colon or rectum 
Most colorectal cancers start as a polyp which is a growth that begins in the inner lining of 
the colon or rectum. Most polyps are not cancerous. Only certain types of polyps such as 
adenomas can become cancerous. Taking out a polyp early, may prevent the cancer to 
appear by not allowing the polyp to become cancerous. 
Over 95% of colon and rectal cancers are adenocarcinomas. These types of cancers start in 
gland cells, like the cells that line the inside of the colon and rectum. There are other types 
of tumors in the colon and rectum (carcinoid tumors, gastrointestinal stromal tumors-
GISTs, lymphomas and sarcomas) (Colorectal Cancer, 2014). 
 
2.2. Etiology of colorectal cancer 
In the medical literature is found that some risk factors might increase the probabilities of 
getting polyps or colorectal cancer. Some of them can be changed; others cannot 
(Colorectal Cancer, 2014). 
 
2.2.1. Risk factors that cannot be changed 
• Age: the risk increases when a person is over 50 years. 90% of the patients 
diagnosed are above 50 years old. 
• Having had colorectal cancer or certain kinds of polyps before. 
• Having a history of ulcerative colitis or Crohn’s disease. 
• Family history of colorectal cancer. 
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• Type 2 diabetes. 
• Certain family syndromes, like adenomatous polyposis (FAP) or hereditary non-
polyposis colon cancer (HNPCC, also called Lynch syndrome). 
 
2.2.2. Risk factors that can be changed 
Some lifestyle-related factors have been linked to a higher risk of having colorectal cancer: 
• Certain types of diets: a diet that is high in red meats (beef, lamb, or liver) and 
processed meats (like hot dogs, bologna, and lunch meat). Cooking meats at very 
high heat (frying, broiling, or grilling) can create chemicals that might increase 
cancer risk. 
• Lack of exercise. 
• Being extremely overweight. 
• Smoking. 
• Heavy alcohol consumption. 
 
2.3. Prevention of colorectal cancer 
2.3.1. Screening tests 
Screening is the process of searching for cancer in people who are asymptomatic. Some 
polyps, or cell growth, can be found and removed before they have the chance to turn into 
cancer. Screening can also help find colorectal cancer early, when it is small and more likely 
to be cured.  
 
2.3.2. Diet and exercise 
Most studies agree that being overweight or obese increases the risk of colorectal cancer in 
both men and women. Having more belly fat which implies a larger waistline, has also been 
linked to colorectal cancer (Colorectal Cancer, 2014). 
In general, diets that are high in vegetables, fruits, and whole grains (and low in red and 
processed meats) have been linked with lower colorectal cancer risk, although it is not 
exactly clear which factors are main leading cause of colorectal cancer. 
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2.4. Finding early colorectal polyps and cancer 
2.4.1. Colorectal cancer screening tests 
Screening tests are used to look for a disease in people who do not have symptoms. In 
many cases, these tests can find colorectal cancers at an early stage and improve treatment 
outcomes. Screening tests can also help preventing some cancers by allowing doctors to 
find and remove polyps that may become cancerous. These tests can be divided into two 
broad groups:  
Test that can find both colorectal polyps and cancer: These tests look at the structure of 
the colon itself to find any abnormal areas. This is done either when a scope is put into the 
rectum or with special imaging (x-ray) tests. The period between tests are suggested by the 
American Cancer Society: 
• Flexible sigmoidoscopy (every 5 years): A flexible, lighted tube is inserted into 
the rectum and lower colon to check for polyps and cancer. 
• Colonoscopy (every 5 years): A longer, flexible tube is used to look at the entire 
colon and rectum. 
• Double-contrast barium enema (every 5 years): This is an x-ray test of the colon 
and rectum. 
• CT colonography - virtual colonoscopy (every 5 years): This is a type of CT scan 
of the colon and rectum. 
Tests that mainly find cancer: These tests examine the stools for signs of colorectal cancer. 
These tests are less invasive and easier to be done than the first type of tests mentioned. 
However, they are less likely to detect polyps. 
• Stool DNA test (sDNA). These tests analyze the stools sample in order to look for 
abnormal sections on DNA from cancer of polyp cells.  
• Fecal Occult Blood Test (FOBT) and Fecal Immunochemical Test (FIT), 
both preferably be made yearly, are samples of stools which are later analyzed for 
blood, which may be a sign of a polyp or cancer. Fecal Occult Blood Test is being 
implemented by the Health Service of Navarra. Specifically, the one with 
quantitative immunological with a cut-off point of 100ng/ml. A single sample is 
collected without dietary restriction. 
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3. ECONOMIC EVALUATION IN HEALTH SERVICES 
3.1. Introduction 
Economic studies establish the most efficient ways to allocate the limited resources a 
society has so the output can be maximized. If the concerning output is health, its inputs 
(factors that are involved in the production of health) must be allocated in the right 
combination so the Pareto optimum can be reached. The inputs that are taken into account 
are, for example, health professionals, time, equipment, buildings, knowledge… Politicians 
or administrative personnel of the health system are the ones who should decide on the 
allocation of these resources. In order to carry out the decision-making, economic 
evaluations are shown as a useful tool because they provide information about the costs 
and benefits a services or a program has. But they will not be the only factor to base the 
decision on, because equity is another factor that should be considered. As Lansdorp-
Vogelaar et al. (2010) say: “Cost-effectiveness analysis, a form of decision analysis, is an 
analytic tool that formally compares the health and economic consequences of different 
interventions, thereby assisting decision makers to identify the interventions that will yield 
the greatest health benefits, given their resource constraints.” 
The economic evaluation of health technologies is to measure the efficiency of different 
alternatives; for instance, implementing a screening program, a surgical instrument or the 
authorization of a new drug. The economic evaluation is comparing the value of the 
resources consumed by an activity or program versus the value of the results provided by 
that activity or program. These studies give the information that the prices provide in a 
competitive economy. They give information in order to allocate efficiently the resources in 
areas such as the public health care system, where there is no market (or it is influenced by 
the government: subsidies, prioritization between health care technologies…). As 
previously mentioned, economic evaluations exist to help to make a decision between 
several options, considering other criteria such as equity and political and social sensitivity. 
 
3.2. Principles of economic evaluation of health technologies 
The aim of an economic evaluation is to measure the outcomes of a technology or a 
program in order to compare the value of the resources consumed in the process and the 
corresponding results. By applying this principle, some tools are available: 
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• Cost-benefit analysis (CBA): compares the incremental cost of a program with its 
incremental benefits in monetary bases. 
• Cost-effectiveness analysis (CEA): is characterized by the use of "natural" 
outcomes, that is, define the outcome depending on the immediate goal of health 
spending. These outcomes can be detected cases, cases of illness avoided, lives 
saved or life-years gained. 
• Cost-utility analysis (CUA): is the most widely used in health economics and 
where results are measured in homogeneous units. This analysis is considered as a 
specific case of CEA, which has as main feature the measuring health outcomes in 
quality-adjusted life year (QALYs). 
 
Cost-effectiveness analysis 
Cost-effectiveness analysis provides a tool to calculate and summarizes benefits, costs and 
harms of a service or a program. That is the reason why this type of analysis can inform the 
decision makers. A mathematical model is used to analyze benefits and costs. 
In order to do a cost-effectiveness analysis, the ICER ratio is commonly used. It is a ratio 
whose numerator is the cost difference of implementing the program which is being tested 
or not implementing a program at all (C0 and C1, respectively), and the denominator is the 
difference between the effectiveness of having or not a program (E0 and E1, respectively). 
This ratio is called Incremental Cost Effectiveness Ratio (ICER): 
     
     
     
 
As Lansdorp-Vogelaar et al. (2010) say: “The (quality-adjusted) life-years gained with a 
particular strategy (compared with an alternative) are included in the denominator, and the 
additional costs of that strategy (compared with the same alternative) are included in the 
numerator, yielding an incremental cost per (quality adjusted) life-year gained.” 
In order to maximize the welfare of the health system, a program that provides a lower 
ICER, would be the one whose cost per unit of output compared to the option of not 
implementing the program are lower. Such analysis can guide policy makers in the 
distribution of funding between different programs in order to achieve a higher level of 
health for the society given the limited resources. The program with lower ICER would be 
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the one providing the greatest health benefits. Policy makers while making a decision will 
also take into account factors such as equity. 
The Incremental Cost-Effectiveness Ratio can compare a program with the alternative of 
not implementing it or with the most efficient technique which has been found so far. A 
program is said to be dominated when its costs are higher and/or its effectiveness is lower 
in comparison to a program whose costs are lower and/or its effectiveness is higher. A 
program is defined as weakly dominated if the opposite situation occurs. Figure 1 helps 
define if a program is dominated by others.  
 
Figure 1. Cost-effectiveness plane. (Source: Drummond; M.F., 2001) 
 
Health care costs. The economic management and clinical management: analytical 
accounting for health care organizations 
The health care institutions are supposed to achieve an appropriate match between the 
resources they use, between the costs and the services they provide. They should try to be 
efficient in their allocation of resources, because by not doing so, it would mean sacrificing 
resources that could be used in alternative activities. 
The financial information these organizations have, can be used to be presented for 
external agents or for internal management. For managers this information is insufficient, 
they need to know the economic and financial aspects of the transformation of resource 
while providing a service. This is what is called analytical, internal management or 
accounting. The techniques used in accounting general ledger intended to decompose into 
useful components for making decisions to answer the questions of where and by whom, 
for what and when. 
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Analytic accounting provides different techniques depending on the cost objectives settle 
by a department and also propose different cost systems. There are several types of 
analytical accounting. Full cost systems are based on the distinction between direct and 
indirect costs; controllable systems distinguishing between controllable and uncontrollable 
costs; variable costs systems distinguishing variables with fixed costs and, finally, relevant 
costs systems against irrelevant costs. 
Probably the most widespread system in health care organizations are the systems whose 
aim is to find the full costs of the total monetary value of resources used to provide a 
service, including both direct and indirect costs. 
Controllable costs systems exist to evaluate the costs over which the personal studied have 
influence in, against those who are out of their control.  
 
3.3. Quality Adjusted of Life Years (QALYs) 
The QALYs are a measure of the outcome of preferences for health states. There are tests 
which establish the utility the individuals have throughout their lives. The result of these 
changes in the health profiles is a measure of the effectiveness of the health interventions 
for these individuals. The QALYs is a health measure combining basic components 
defining health, that is, the quantity and quality of life. The QALYs are calculated by 
multiplying the life expectancy by a weight that reflects quality. The concept which lies 
behind the QALY is that years of life should not be calculated without weighting the health 
benefits, but must be adjusted or weighted by the quality of those years the patient is alive 
due to the program. 
The QALYs are a measure of the state of health provided by the quality of life of the 
difference of having a program against the possibility of not having it. This measure is 
ranged from 0 to 1, where 1 represents perfect health and 0 corresponds to a state of health 
corresponding to death. There is a possibility in which this measure can take negative 
values, implying a stage where the patient is worse than being death. 
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Figure 2. QALYs gained with the intervention of the program. (Source: Drummond; M.F., 2001) 
 
In Figure 2 can be observed two programs corresponding to variations in health of an 
individual due to a health program (the existence of a program versus the non-existence of 
it). The area between the two programs is the health gain produced due to the program. 
There are several instruments for measuring quality of life associated with health that serve 
developing the QALY, such as the EQ-5D. The EQ-5D is an instrument that has been 
developed by the EuroQol group. This group was founded in 1987 and was the first to 
make a test of the feasibility of a standardized instrument to describe and value health on 
quality of life, without referring the test to any specific disease. The existence of 
standardized tools holds a great importance because these standardized instruments are the 
ones which allow comparing the cost-utility of different programs. 
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4. PROGRAM FOR EARLY DETECTION OF COLORECTAL CANCER IN 
NAVARRA 
4.1. Situation of colorectal cancer in Navarra 
4.1.1. Incidence rate 
According to the Cancer Record of Navarra (Registro de Cancer de Navarra) (2003-2007), 
the colorectal cancer is the third most common tumor in men (15.1% of total cancers), 
behind lung and prostate; and the second in females (14.46% of all cancers), behind breast 
cancer. If both genders are considered, the colorectal cancer is the most common. These 
rates cannot be generalized to the whole Spanish population because each autonomous 
community has different incidence rates.   
 
Figure 3. Incidence rate of cancers in men and women in Navarra. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
According to the latest data of the Cancer Record of Navarra (2003-2007), the tumor is 
more likely to appear at 50 years, increasing with the age. The incidence is very low when a 
person is below the 50 years. 
 
Figure 4. Incidence of colorectal cancer in men and women in Navarra through the life time. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
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CRC incidence shows an increasing trend since 1973, for both men and women, with a 
greater increase among men. 
 
4.1.2. Survival rate 
According to data from EUROCARE 46 study, the five-year relative survival of patients 
diagnosed with colorectal cancer in Europe, during the period 1995-1999 was 54%. 
According to the same source, the survival rate of colorectal cancer during the same period 
in Spain was 53,65%. 
 
4.1.3. Mortality rate 
Colorectal cancer is the second tumor that causes more cancer deaths for men in Navarra, 
behind lung cancer. For women in Navarra, colorectal cancer is the first cancer that causes 
more deaths, being the second breast cancer and third lung cancer. 
  
 
Figure 5. Mortality rate of cancers in men and women in Navarra. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
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4.2. Early detection program 
4.2.1. Justification 
Screening for early detection of colorectal cancer has proved to be effective through all the 
literature. These articles also state that this screening program also reduce the mortality rate 
significantly. 
The benefit of a screening test is obtained by applying an early treatment for malignant 
lesions detected in early stages. If a screening is performed, there is a likelihood of 
decreasing the colorectal cancer incidence because benign polyps can be detected (before 
they become cancerous) and can be removed, so the appearance of illness is prevented. 
 
4.2.2. Objectives 
Main objective  
 Reduce the incidence of colorectal cancer.  
 Reduce mortality from colorectal cancer.  
 Improve the quality of life of patients who are diagnosed colorectal cancer.  
 
Secondary objectives  
 Achieve at least 60% of participation (willingness to participate in the program) of 
the people who are invited to the program for the first time and 80% of adherence 
(willingness to remain in the program once the screening test has been delivered to 
the patient’s home). 
 Ensure a track and continuity of care for all participants, ensuring proper 
coordination between different services and levels of care involved, in order to 
achieve an early diagnosis and as early treatment as possible.  
 Establish a plan that would ensure an optimal quality level and adequate quality in 
the performance of the test screening and diagnostic confirmation phase and 
treatment. 
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4.2.3. Basis of the program  
Target population 
The target of the program for the early 
detection of colorectal cancer are 
asymptomatic men and women living in 
Navarra, between 50 and 69 years with an 
average risk of developing the disease. 
People with family risk factors and/ or 
factors determining high risk are not a 
target; they will be included in specific 
programs.   
According to the 2012 Census, 165,934 
people reside in Navarra aged between 50 
and 69 years, almost half men and half 
women.  
124,017 people in the target age (75%) live in the health area of Pamplona, 24,237 (14%) in 
the health area of Tudela and 17,680 (11%) in the health area of Estella. 
 
Screening test 
As a screening test, a Fecal Occult Blood Test (FOBT) will be used. It is a quantitative 
immunological test with a cut-off point of 100 ng/ml. A single sample is collected without 
dietary restriction.  
As the American Cancer Society describes, “The Fecal Occult Blood Test (FOBT) is used 
to find occult blood (blood that can't be seen with the naked eye) in feces. The idea behind 
this test is that blood vessels at the surface of larger colorectal polyps or cancers are often 
fragile and easily damaged by the passage of feces. The damaged vessels usually release a 
small amount of blood into the feces, but only rarely is there enough bleeding for blood to 
be visible in the stool. 
The FOBT detects blood in the stool through a chemical reaction. This test cannot tell 
whether the blood is from the colon or from other parts of the digestive tract (such as the 
stomach). If this test is positive, a colonoscopy is needed to find the cause of bleeding. 
Although cancers and polyps can cause blood in the stool, other causes of bleeding may 
Figure 6. Target population of the screening program in 
Navarra. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de 
Navarra, 2012) 
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occur, such as ulcers, hemorrhoids, diverticulosis (tiny pouches that form at weak spots in 
the colon wall), or inflammatory bowel disease (colitis).” The significant gastrointestinal 
diseases leading to cancer are, for example, ulcerative colitis, Crohn's disease or polyposis. 
 
Range of exploration 
The interval between tests is set to 2 years. Depending on the detected pathology, 
protocols for specific trace will be established. 
 
4.2.4. Operating plan 
Identification of the target population  
Given the nature of the program (population-based), the primary source of data used to 
identify the target population will be the last update of the census of Navarra. 
As stated, the women and men whose residence is Navarra and are aged between 50 and 69 
years. 
Navarra resident population born between 1 January 1944 and 1931 December 1964 will 
be considered for the first round of the program, November 2013 and July 2015. Those 
born in the years 1965 and 1966 will be included in the second round. Although in this 
second round the people who were born in 1944 and 1995 should leave the program 
because they overcome the target age. For the third round, people who reach the target age 
will be included and those who have overcome the target age will leave the program 
(Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012). 
 
Identification of the eligible population 
All individuals who meet the following conditions should be excluded: 
 Personal history of colorectal cancer. 
 Personal history of adenomas, in which specific tracks have been performed. 
 History of colon pathology susceptible of being monitored with colonoscopy 
(ulcerative colitis, Crohn's disease, attenuated familiar adenomatous polyposis…) 
and family-related hereditary syndromes for colorectal cancer. 
 Family history of colorectal cancer with high-risk criteria: 
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o 2 or more relatives with first degree of relation (parents, children, 
siblings…) 
o 1 family member of first degree-relation with lower age at diagnosis of 60. 
 People who have had a colonoscopy in the last 5 years, regardless of the reason 
why it was performed (permanent or temporary exclusion depending on the subject 
if known).  
 Those exhibiting symptoms suggestive of a severe coagulopathies disease that 
prevent the realization of a colonoscopy, or carry a total colectomy. 
 Patients in palliative care programs. 
 Terminal illness and serious illness or disability that contraindicates further study of 
the colon. 
 
Overall planning and programming 
The planning is implemented in the three health areas in Navarra: Tudela, Pamplona and 
Estella.  
Full coverage of the target population will take place in 4 years in a 2 rounds program.  
During the first round between November 2013 and July 2013, half the population is 
invited from each of the health areas. The second invitation for the people of the first 
round and the first invitation for rest are held during the second round, September 2015 to 
July 2017. This means, that by July 2017, all people living in Navarra identified as the 
population target will be invited at least once.  
 
The health areas to be included for the rounds are: 
Tudela’s health area: 
 
Figure 7. Rounds in Tudela’s health area for the screening program in Navarra.  
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
In Tudela’s area, 12,005 people are included. 
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Pamplona’s health area: 
 
Figure 8. Rounds in Pamplona’s health area for the screening program in Navarra.  
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
The target population Pamplona area has is 65,658 people.  
 
Estella’s health area: 
 
Figure 9. Rounds in Estella’s health area for the screening program in Navarra.  
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
In the area of Estella, 8,479 people will be invited to be part of the program. 
 
Population awareness  
In population-based screening programs, the outcome of reducing the incidence and 
mortality of the disease is usually achieved in a period of ten years. 
But to achieve this aim of the program, the response of the target population is essential. It 
is necessary to achieve at least a 60% of participation. Due to this reason, a sensitivity 
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campaign needs to be implemented. The objective is not only the target population (50-69 
years old), but also to health professionals and the population as a whole. 
In addition to the personalized information the eligible population will receive, there are 
scheduled specific information and awareness actions for the health personnel involved 
(primary and specialized care professionals: digestive, anesthesia, pathology, surgery, 
radiology, oncology…). 
The Institute of Public Health and Labor is also requesting the assistance of more than 
10,000 companies and entities that can encourage the participation (pharmacies, 
municipalities, self-help groups, associations, clubs…). 
Moreover, a communication campaign with the slogan "Choose 90. A simple test can save 
your life" is being conducted referring to the 90% of colorectal tumors which are curable if 
they are detected on time. The campaign includes print ads, radio, brochures, and posters 
in buses shelters and in buses. There is also a web-page available, 
www.cancercolon.navarra.es, with relevant information about the program and the access 
to the campaign. 
All this measures are expected to increase the awareness of this type of cancer and the 
participation rate which will lead to a greater health benefit and cost-effectiveness of the 
screening program.  
 
Detection and confirmation process 
The participation in the program is developed as follows: 
 Invitation. When the program starts in a health area, the target population 
belonging to that area receives a personalized invitation letter which is sent to their 
homes. In it, it is explained the campaign content. It includes the option to send the 
card to the issuer expressing the willingness to participate in the program. 
 Confirm participation. To participate in the program, the patient can send the 
card by post to the address of the issuer. But the card can also be given to the 
health center in which the patient is enrolled, by calling to the following number: 
848 42 34 98 or by sending an email to the address precolon@navarra.es. 
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 Reception of the Kit. Days after showing the desire to participate, the person will 
receive at home a kit for sample collection and data tagged with the participant 
name and a letter with instructions explaining how to perform the process of 
sampling and where to deliver it. 
  
 
Figure 10. Instructions for the sample collection. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
 Sample delivery. Once the test is done, the kit with the sample must be delivered 
to the health center. It should be deposited in a specific container identified with 
the program logo. 
 Reporting of results. Once the samples are analyzed, negative results will be 
communicated by letter and positive results (if blood is detected in the stools) will 
be communicated personally and the patient will be referred to his/her health 
center to carry out a clinical evaluation and diagnostic confirmation. 
It is estimated that the test will be positive in about 70 of every 1,000 people, but 
only 3 will be confirmed with colorectal cancer. In 1 out of 3 positive FOBT, the 
presence of blood will be due to the existence of benign polyps which should also 
be treated to avoid the future appearance of cancer. 
To find the source of bleeding a colonoscopy will be performed. This is a scan 
inside the intestine that is performed with sedation to prevent it from being painful. 
It will help visualize, detect and remove the lesions that have caused the bleeding. 
Thus, there are more benefits than being able to apply an early treatment for 
cancerous tumor through the test. This screening program also removes precursor 
lesions and, consequently, avoids the appearance of the disease. 
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5. COST-EFFECTIVENESS ANALYSIS OF COLORECTAL CANCER 
SCREENING 
In the past decades, a vast amount of articles have been published about the effectiveness 
of the screening for colorectal cancer. Several strategies have been tested; they have been 
compared using Quality Adjusted Life Years (QALYs) or Life Years Saved (LYS). 
Sensitivity analyses have also been implemented and the databases used to compare the 
different screenings are known globally. 
The first article analyzed is “The cost-effectiveness of screening for colorectal cancer” 
which was published in CMAJ in 2010 (Telford, Levy, Sambrook, Zou, Enns). 
This article is an evaluation about the screening for colorectal cancer which has been 
proved to be cost-effective. 10 strategies have been tested for colorectal cancer screening, 
including no screening. In this research, incremental cost-effectiveness has been estimated, 
as well as quality of life and costs of each strategy. 
In order to estimate the costs, the perspective of a third-party has been established. This 
means that the cost of the patients and the cost of those who take care of them are not 
taken into account. In order to calculate the QALYs (Quality-Adjusted Life Years), the 
strategies have been compare with the no screening alternative. The model method used is 
the Markov model. 
This research was done to test the cost-effectiveness of screening for colorectal cancer. 
Even though 10 strategies are being considered, this evaluation paper has focused on those 
which are being implemented in the population (average-risk Canadians) screening 
programs in the Canadian provinces (colonoscopy – every 10 years, annual fecal 
immunochemical test, annual low-sensitivity guaiac fecal occult blood test). The incidence 
rate has been reduced by 81%, 65% and 44%, respectively, comparing with no screening; 
and the mortality rate has been reduced by 83%, 74% and 55%. The QALYs per each 
program are $6133, $611 and $9159. After applying a probabilistic sensitivity analysis the 
data has been found to be robust (Telford MD, et al., 2010). 
Screening for colorectal cancer is cost-effective taking into account the established 
threshold of willingness to pay 30,000 €/QALY (Sacristan, et al., 2002). Annual fecal 
immunochemical test and colonoscopy every 10 years offer the best value for the money in 
Canada. 
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Figure 11. Cost-effectiveness acceptability curve. (Source: Telford MD, et al., 2010) 
 
 
Table 1. Cost and effectiveness of three strategies for screening for colorectal cancer. 
(Source: Telford MD, et al., 2010) 
 
The second article analyzed is “Cost-effectiveness of colorectal cancer screening” which 
was published in Epidemiologic Reviews in 2011 (Lansdorp-Vogelaar, Knudsen, and 
Brenner). 
This article shows that numerous colorectal cancer screenings have proved to be effective 
in decreasing colorectal cancer mortality. The timeline of the databases searched were 
between January 1993 and December 2009. After an extensive search in the literature, the 
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conclusions of this article are that all the screening strategies are cost-effective and some of 
them even cost-saving comparing with no screening.  
Nevertheless, the articles differ in which is the most effective one or which one has the 
best incremental cost-effectiveness ratio given the willingness to pay per life-year gained. 
There was consensus about computed tomographic colonography, capsule endoscopy and 
stool DNA testing are not yet cost-effective in comparison with the established screening 
options. 
 
 
Table 2. Cost and effectiveness of the strategies for screening for colorectal cancer. 
(Source: Lansdorp-Vogelaar, et al., 2011) 
 
The third article analyzed is “Colorectal cancer screening for average-risk North 
Americans: an economic evaluation” which was published in PLOS Medicine in 2010 
(Heitman, Hilsden, Au, Dowden, Manns). 
The aim of this article was to do an economic analysis of colorectal screening in average 
risk North American individuals considering all screening alternatives and current 
colorectal treatment costs. 
Incremental cost-utility analyses were made using the Markov model. Fecal 
Immunochemical Test (FIT) annually (divided by low, mid and high test performance), 
guaiac-based Fecal Occult Blood Test (FOBT), fecal DNA every 3 years, flexible 
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sigmoidoscopy or computed tomographic colonography every 5 years, and colonoscopy 
every 10 years were strategies tested for this economic analysis. All programs were 
compared to the alternative of a no screening program. Annual FIT (mid test performance) 
was more effective and less costly compared to the rest of strategies (including no 
screening) except the alternative of FIT-high. The percentage of cancers that could be 
reduced is from 4.857% to 1.782% and the percentage of CRC deaths is from 1.393% to 
0.457% (Heitman, et al., 2010). 
CRC screening with FIT decreases the probability of CRC and deaths related to colorectal 
cancer, and reduces health care costs if it is compared with no screening and to other 
existing screening strategies.  
 
Figure 12. Probabilistic sensitivity analysis. (Source: Heitman, et al., 2010) 
 
Table 3. Base case incremental cost per QALY gained for average risk patients. (Source: Heitman, et al., 2010) 
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The fourth article analyzed is “Preliminary analysis of the cost-effectiveness of the National 
Bowel Cancer Screening Program; demonstrating the potential value of comprehensive real 
world data” which was published in Internal Medicine Journal in 2011 (Tran, Keating, 
Ananda, Kosmider, Jones, Croxford, Field, Carter and Gibbs). 
An economic analysis was made by the government health care point of view. Specially, an 
incremental cost-effectiveness analysis, comparing the Australian database of the National 
Bowel Cancer Screening Program (NBCSP) with the alternative of no screening. The 
effectiveness was expressed as CRC-related life years saved (LYS).  
The conclusion of this article is that along the lifetime of the people tested in the sample 
and the program being compared with the alternative of no screening, the effectiveness of 
the NBCSP was 1,265 life years saved; avoid 225 CRC cases and a cost-effectiveness ratio 
of $38,217 per LYS. If the 100% had been participated in the program the cost-
effectiveness ratio would have improved up to $23,395 (Tran, et al., 2010). 
The fifth article analyzed is “Review of economic evidence in the prevention and early 
detection of colorectal cancer” which was published in Health Economics Review in 2013 
(Jeong and Cairns). 
This article shows the economic conclusions of the colorectal cancer screenings published 
from 1999 to 2012. The databases used were MEDLINE, EMBASE, National Health 
Service Economic Evaluation (NHS EED), EconLit, and HTA. Different combinations of 
screening for mass CRC screening programs are described as well as adequate follow-up 
tests in order to guide the decision makers through the most appropriate policy. One 
example of the cases analyzed is the article published in 2007 by Pickhardt which compares 
the Computerized Tomography Colonography with a 6-mm threshold with the alternative 
of no screening. One of the results is that the program is cost-effective since the outcome 
is $4,361 per LYG. 
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6. COST-EFFECTIVENESS ANALYSIS OF THE PROGRAM FOR EARLY 
DETECTION OF COLORECTAL CANCER IN NAVARRA 
In order to analyze the costs of the colorectal cancer screening program, two perspectives 
will be implemented. The first one is the Health Service Provider which only takes into 
account the costs of equipment, time of the health professionals such as specialists and 
nurses, medicines, etc. This means only direct costs are estimated. The second point of 
view is the one of the patient who is been tested through a screening for colorectal cancer, 
his/her time and the time of his/her family members. 
Invitation. When the program starts in a health area, the target people belonging to that 
area receive a personalized invitation letter which is sent to their homes. The invitation 
procedure is important since no time is required by the patient in order to get the 
invitation. However, a previous time is needed by the “Instituto de salud pública y laboral, 
sección de detección precoz” for the search of the people who are the target population for 
the program in the data base “padrón municipal” and a further search to select those who 
are eligible. In the letter is explained the campaign content. It includes the option to send 
the card to the issuer expressing the willingness to participate in the program. It also has to 
be taken into account the time consumed by the “Instituto de salud” for creating the cards 
with the information for the screening program. 
 
 
Figure 13. Letter and participation card sent to the target population. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
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Confirm participation. To participate in the program, the patient can send the card by post 
to the address of the issuer. The card is pre-stamped which implies that the cost of delivery 
is paid by the health service. But the card can also be given to the health center in which 
the patient is enrolled, by calling to the following number: 848 42 34 98 or by sending an 
email to the address precolon@navarra.es. Nevertheless, there is a physiological cost 
implied for those who are the target population (50-69 years old). People may become 
aware of their probabilities to have colorectal cancer or start thinking about this topic 
which were not on their minds until the card was sent to them or until they realize that 
colorectal cancer is in the top three for incidence and mortality through the sensitivity 
campaign. 
Sensitivity campaign. In population-based screening programs, as it is the case, the 
objective is to decrease incidence and mortality and this is achieved if the patients who are 
asked to participate in the program do so. This means, that a sensitivity campaign is needed 
in order to make the population aware of the problems of colorectal cancer and the 
benefits of participating in the program.  
A program is considered effective if it achieves at least a 60% of participation. Due to this 
reason, a sensitivity campaign needs to be implemented. The objective is not only the target 
population (50-69 years old population), but also to health professionals and the population 
as a whole. 
Moreover, in addition to the personalized information the target population will receive, 
there are scheduled specific information and awareness actions for the health personnel 
involved (primary and specialized care professionals: digestive, anesthesia, pathology, 
surgery, radiology, oncology…). All these programs are taken as costs too: the time while 
the information meeting is taking place as well as the time of the personnel to organize 
those meetings. 
The Institute of Public Health and Labor is also requesting the assistance of more than 
10,000 companies and entities that can encourage the participation (pharmacies, 
municipalities, self-help groups, associations, clubs…). At this stage of implementation of 
the program sensitivity the costs taken into account are those of the administrative time 
consumed by the health system.  
In addition, a communication campaign with the slogan "Choose 90. A simple test can save 
your life" is being conducted referring to the 90% of colorectal tumors which are curable if 
they are detected in time. The campaign includes print ads, radio, brochures, posters in 
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buses shelters and in buses as well as a web www.cancercolon.navarra.es with relevant 
information about the program where people can also learn about the accessions to the 
campaign. All the costs related to campaign (radio advertisement, print ads, making them) 
and the administrative paperwork behind it are also taken into consideration. 
 
Figure 14. Screenshot of the web page of the program of colorectal cancer. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
Reception of the Kit. Days after showing the desire to participate, the person will receive at 
home a kit for sample collection and data tagged with the participant and a letter with 
instructions explaining how to perform the process of sampling and where to deliver it. 
The cost implied in this stage of the process are those linked to the administrative 
personnel while sending the kit to those patients who have shown they desired to 
participate in the screening.  
For convenience, the kit can also be taken in the health center or in the pharmacy.  
 
Figure 10. Instructions for the sample collection. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
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The Fecal Occult Blood Test can be done at home, there is no need of stopping taking any 
medication and no special diet is needed. However, the sample must not be taken if the 
patients (women) are menstruating or if the patient has bleeding hemorrhoids. 
Sample delivery. Once the test is done, the kit with the sample must be delivered to the 
health center in a maximum of three days. It should be deposited in specific containers 
identified with the program logo. Transportation costs are linked to the patient since there 
is time and money involved in the transportation of the sample from the patient’s home to 
his/ her health center. However, there is no need to wait in a queue or to make an 
appointment because there is a specific container in each health center. 
 
 
Figure 15. Sample kit to collect the stools. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
Reporting of results. Once the samples are analyzed, results will be given in a maximum of 
15 days. If the results are negative, the results will be communicated by letter. But if the 
results are positive, if blood is detected in the stools, the nurse assigned to the program will 
communicate personally to the patient the results and the patient will be referred to his/her 
health center to carry out a clinical evaluation and a diagnostic confirmation. The waiting 
time for the patient is critical not only for the effectiveness of the program but also for the 
restlessness of the patient the days before the test is done and while waiting for the results. 
If the results are negative the patient is aware of how the government implements policies 
which increase the welfare of the society and feels relieve knowing that the result of the test 
implies he/she does not have colorectal cancer. Nevertheless, the patient is thinking 
through the whole process of the possibility of having colorectal cancer and the 
consequent problems which lead to a decrease in his/her well being.  
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It is estimated that the test will be positive in about 70 of every 1,000 people, but only 3 
will be confirmed with colorectal cancer. In 1 out of 3 positive, the presence of blood will 
be due to the existence of benign polyps which should also be treated to avoid the future 
appearance of cancer. 
 
Positive result test/colonoscopy. To find the source of bleeding a colonoscopy will be 
performed. This is a scan inside the whole intestine that is performed with sedation to 
prevent it from being painful. It will help visualize, detect and remove the lesions 
(suspicious looking areas such as polyps) that have caused the bleeding. Thus, there are 
more benefits than being able to apply an early treatment for cancerous tumor through the 
test. This technique removes precursor lesions and, consequently, avoids the appearance of 
the disease. 
The patient should also sign a paper in which he/she consents being done a colonoscopy. 
Through the whole process, gastroenterologist, anesthetist and nurses’ time are considered, 
and the cost of the colonoscope are taken into consideration too. 
The colon and rectum should be clean by the time the colonoscopy is performed, so the 
doctor can see the inner linings during the test. The patient should take laxatives the day 
before the exam, an enema that morning and a special diet the previous days. As the 
American Cancer Society suggests, the diet should consists of drinking clear liquids (water, 
apple or cranberry juice, and any gelatin except red or purple) for at least a day before the 
test. Plain tea or coffee with sugar is usually okay, but no milk or creamer is allowed. Clear 
broth, ginger ale, and most soft drinks or sports drinks are usually allowed unless they have 
red or purple food colorings, which could be mistaken for blood in the colon. 
The night of the test the patient will be told not to eat or drink anything after midnight the 
night before the test. If the patient takes prescription medicines, the doctor will suggests 
the steps which should be followed. 
Once the patient is in the hospital, the anesthetist will provide the patient with sedation in 
order to prevent the colonoscopy to be painful. The colonoscopy will be performed lasting 
approximately 20 minutes and after that the patient will be moved to a recovery area in 
which the doctor will check if the person is recovering as he/she should be. The doctor 
will advice not to take an important decision that day and inform that the patient will have 
a small drowsiness, lack of reflections and probably really angry. A family member should 
be needed through the whole process.  
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If the bowel preparation has been inadequate and colon is not clean another colonoscopy 
should be made and the diet previous the test should be done again. 
 
Colonoscopy’s results. 
An appointment with the gastroenterologist must take place so as to inform the patient 
about the results of the colonoscopy. 
Significant benign pathology.  
The patient will be cited in the Department of Gastroenterology for assessment. The 
nurses in charge of the screening program will send the patient a letter with the day of the 
appointment. The result of the test taken in that appointment will be provided by phone or 
letter in order to minimize the potential negative effects of the waiting queues. According 
to the final outcome of such assessment, the doctor would provide the appropriate 
monitoring. 
Polyps and/or adenomas.  
If those benign polyps or adenomas found require special controls, the follow-up will be 
according to the protocol adopted following the recommendations of the European 
Guidelines. The high-risk adenomas requires colonoscopy every year and intermediate-risk 
every 3 years. The low-risk adenomas return to the PDPCCR (if not excluded by age). 
 
Cancer treatment.  
If malignant adenomas are found, the patient will be performed a blood test and an 
electrocardiogram for more information for future events. The patient is required to assist 
to an appointment with the oncologist and solutions such as chemotherapy, radiation 
therapy, surgery and a combination of those options will be mentioned. Through this 
process nursing assistant, specialists, operating room, surgical instruments costs … are 
taken into consideration. 
The early detection of this type of cancer is really important because if it is detected in a 
high stage (stage D, using Duke’s stage at diagnosis), there is a possibility of using a bag as 
the last step of the digestive system and this solution to the illness can lead to allergies. 
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6.1. Cost of the program for the Health Service Provider 
The analysis of the costs of the screening for colorectal cancer which follows, has only 
taken into account the cost for the Health Service Provider. This means that only direct 
costs for the Servicio Navarro de Salud have been accounted. Those costs are the ones 
mentioned before: costs of equipment, time of the health professionals such as specialists 
and nurses, medicines, etc. Costs generated by screened men and women (transportation, 
loss of working hours, colonoscopy-associated intangible costs) have not been taken into 
account.  
Other direct costs for the health provider have not been accounted for. These are: sending 
the FOBT kit by mail, leaflets, letter with the identification sticker for the sample test, the 
software for the program, the free phone line and other expenses such as trips of the 
coordination team. 
If initial participation of 60% is 
assumed, the volume of samples 
which should be processed would 
be 23,258 annually. 
 
Table 4. Estimation of the samples collected in one year. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
According to the data of the prevention program, it is estimated that 7% of the sample will 
be positive. This leads to 1,628 positive Fecal Occult Blood Test. 
 
Table 5. Estimation of the positive results from the Fecal Occult Blood Test in one year. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
36 
 
According to the population figures and participation rate, 1,758 colonoscopies will be 
performed annually so as to confirm the diagnosis of cancer. This amount of 
colonoscopies also includes the ones which have been made again for poor preparation of 
the patient or for an incomplete result.  This explains why the number of colonoscopies is 
higher than the number of positive test for fecal occult blood. 
 
Table 6. Estimation of the colonoscopies performed due to the screening program. 
(Source: Programa de Detección Precoz de Cáncer Colorectal de Navarra, 2012) 
 
To sum up, it is estimated that about 70 in every 1,000 people taking the test will be 
positive, but only 3 will be confirmed to have cancer. In 1 out of 3 positive cases, the 
presence of blood will be due to the existence of benign polyps that should also be treated 
to avoid the future appearance of cancer. 
The following table (table 7) shows the cost of the program described above. These costs 
also show the recruitment of a doctor and two nurses. The costs described are unitary costs 
of the health system provided by the web page of the community of Navarra 
(www.navarra.es). 
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Price 
(2014 €) 
Patients 
With 
program 
Without 
program 
Doctor salary (A) 25,281.76 1 25,281.76 
 
Nursing  salary (B) 21,268.80 2 42,537.60 
 
LABORATORY 
    
-  Microbiological analysis with      
identification (known germ) 
31.29 23,258 727,742.82 
 
PRIMARY CARE SERVICES 
    
-  Medical check (7% FOBT) 84 1,628 136,752 5,860.80 
GASTROENTEROLOGIST 
    
-  Colonoscopy with or without 
biopsy 
535 1,758 940,53 37,327.71 
-  First visit 220 70 15,4 
 
ONCOLOGY 
    
-  First visit 220 70 15,4 15,4 
TOTAL COST OF THE 
PROGRAM   
1,903,644.18 58,730.00 
 
     Table 7. Estimation of the total cost per year of the screening program and the alternative of not implementing it. 
 
The program will cost annually 1,903,644.18€ in contrast with the alternative of not 
implementing the program: 58,730.00€; being the difference 1,844,914.18€. 
 
6.2. Effectiveness 
The effectiveness of the program for early detection of colorectal cancer has been taken 
from the literature (Telford MD, et al., 2010). 
The data taken is the Quality Adjusted Life Years gained for the screening test of low-
sensitivity guaiac Fecal Occult Blood Test (performed annually) as show in the following 
table: 
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Table 1. Cost and effectiveness of three strategies for screening for colorectal cancer. 
(Source: Telford MD, et al., 2010) 
There are other factors which reflect the effectiveness of the screening test using low-
sensitivity guaiac fecal occult blood test. These measures are decrease in mortality rate 
(55%) and decrease in incidence (44%). 
These quantities are the ones which have been chosen because the low- sensitivity guaiac 
fecal occult blood test is the closest to the one being implemented in Navarra (quantitative 
immunological fecal occult blood test). However the range of exploration is different since 
the test from the literature has been performed annually and the interval between tests for 
the screening test in Navarra is performed every two years. This limitation should be taken 
into account. 
This data applied to the program for the early detection of colorectal cancer in Navarra is 
the one shown below. It shows the effectiveness of the quantitative immunological Fecal 
Occult Blood Test for colorectal cancer over the lifetime of 23,258 individuals who are 
expected to participate in the program anually, relative to not screening. 
 
 
Table 8. Effectiveness estimators of the screening program using Fecal Occult Blood Test. 
 
*(23,258/100,000*6914) 
Quantitative Immunological Fecal Occult Blood 
Test, relative to no screening 
Quality Adjusted Life Years 
Gained 
1,608* 
Decrease in mortality 55% 
Decrease in incidence 44% 
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However, this result is an approximation of the cost and effectiveness of the program 
which has not still finish the first round. This outcome is subjected to modifications and a 
more accurate analysis of the costs. 
 
6.3. Incremental Cost Effectiveness Ratio (ICER) 
The early detection program of colorectal cancer will cost annually 1,903,644.18€ in 
contrast with the alternative of not implementing the program: 58,730.00€. This means that 
the variation of implementing the program versus the alternative of not implementing it, is 
1,844,914.18€.  
The effectiveness analysis has been taken from the literature and if the information found 
in the article mentioned before is approximated to the number of patients who participate 
annually in the program in Navarra, the Quality Adjusted Life Years gained (comparing 
with no screening) is 1,608. 
 
     
     
     
  
             
         
         
 
    
   
 
This implies that the cost-effectiveness ratio is 1,147.29€ per Quality-Adjusted of Life-
Years gained, which is cost-effective because this quantity is under the threshold of 30,000 
€/QALY (Sacristan, et al., 2002). 
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7. LIMITATIONS 
This study was made given the following restrictions. Model-based economic evaluation is 
subject to the existing data in the medical literature, which is under constant change. When 
a new article comes out, the previous ones become outdated. It should also be considered, 
as Lansdorp-Vogelaar et al. (2010) say, that: “The natural history of colorectal cancer is 
based on assumptions regarding the progression from adenoma to carcinoma and the 
transition time from a low-risk polyp to a malignant neoplasm.” 
Another limitation is the untested assumptions considered to analyses the screening 
program for colorectal cancer: participation and acceptation rates, characteristics of the 
Fecal Occult Blood Test, incidence of adenomas, number of colonoscopies made by bad 
performance …. The model has not taken into account the infrastructure of the costs of 
the Health Provider (Servicio Navarro de Salud) such as buildings and its maintenance, 
transportation costs for the FOBT screening test and so on. 
The model studied has the perspective of a third-party payer; this means that only direct 
costs are estimated without taking into consideration the cost for the patient and his/her 
family. Only cost from the health care system has been accounted and not the one from 
the societal perspective. 
The economic analysis of the program for early detection for colorectal cancer has been 
done with the prices of Navarra’s Health System. Therefore, the direct comparison 
between countries is limited. However, it can be useful if the health care system is similar 
to the one in Navarra. As Lansdorp-Vogelaar et al. (2010) say: “Generalization of cost-
effectiveness analyses from one country to another cannot be done, because screening 
costs, resource capacity and population preferences for different screening tests vary from 
country to country.” Moreover, the costs analyzed for the Health System in Navarra are the 
ones up to the first visit to the oncologist. This is an important constraint because the cost 
of colorectal cancer treatments vary on the stage the cancer is found. The higher the stage 
the cancer is found, the higher the cost of the treatment. 
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8. CONCLUSION 
In this article, the importance of colorectal cancer has been explained through indicators 
such as incidence, survival and mortality rate. This type of cancer is a problem for all the 
developed countries. In Europe, the European Union Council advices to implement  a 
program of early detection for colorectal cancer  using a Fecal Occult Blood Test as a tool 
to do the screening program. It has also been explained what are the risk factors that cause 
this disease as well as the types of screening test according to the invasion level. 
The reasons why an economic evaluation is crucial for a decision-maker have been exposed 
as well as the main principles used for an economic evaluation of a health technology. The 
most common economic evaluation techniques are: cost-benefit analysis, cost-effectiveness 
analysis and cost-utility analysis. Given these evaluating methods, the outcomes of the 
money spent in a specific program or technology can be analyzed, showing the relation 
between the resources and the results of those resources consumed. However, an 
economic analysis is only one of the factors that a politician should take into account; 
because there are factors such as equity and social sensitivity that should also be 
considered. 
An analysis of the situation of the colorectal cancer in Navarra has also been made by using 
the Sistema Nacional de Salud, Padrón de Navarra and the  resources the Instituto de Salud Pública 
y Laboral, sección de Detección Précoz, has, for example the Registro de Cáncer de Navarra. 
International databases have also been used such as the Eurocare. In addition, an 
explanation about the objectives of the program has been made; these goals are the 
reduction of the incidence and mortality from colorectal cancer. The target population are 
women and men between 50-69 years old (population at average risk of developing the 
disease). Since the program is population-based, the participation rate is crucial, that is why 
along this months an awareness campaign is been implemented. 
Implementing this screening program increases the welfare of the people tested because if 
the disease is detected early, it can dramatically change the course of the illness. And the 
cure rate can also be increased. Moreover, an appealing fact to do this screening test is that 
a colonoscopy (a further test of the screening) can detect polyps. These precursor lesions 
can be removed and can prevent the cancer cycle form beginning in the first place. 
The costs of the program which have been analyzed have been the direct costs to the 
health provider. However, the costs for the patients and their families have only been 
described. 
42 
 
The sum of these costs and the costs of the alternative of not implementing the program, 
provide the information to calculate the Incremental Cost-Effectives Ratio (ICER). This 
measure is one tool of the cost-utility analysis. The numerator is the difference of costs and 
the denominator of this ratio is the effectiveness of the program versus the alternative of 
not implementing it. The program will cost annually 1,903,644.18€ in contrast with the 
alternative of not implementing the program: 58,730.00€. This implies a difference of 
1,844,914.18€ per year. The effectiveness of the program has been calculated by adapting 
the Quality Adjusted of Life Years (QALYs) obtained from the literature to the specific 
case of Navarra. The result proves the screening program in Navarra to be cost-effective 
since the result is below the threshold of 30,000 €/QALY for efficiency (Sacristan, et al., 
2002). The ICER is 1,147.29 €/QALY which means that in order to gain a Quality-
Adjusted of Life-Years the government would need to spend 1,147.29 €. 
There has also been a review through the literature about economic evaluations for the 
different types of screening test for colorectal cancer. These analyses have been made by 
using Quality Adjusted Life Years (QALYs) or Life Years Saved (LYS). There have also 
been found other indicator of effectiveness such as decrease in mortality and decrease in 
incidence. All the articles conclude that the screening tests are cost-effective. However, not 
all agree which tests are dominated by the rest of screening tests. The tools to achieve these 
conclusions have been incremental cost, incremental cost-effectives ratio, cost-
effectiveness acceptability curve or probabilistic sensitivity analysis. 
In conclusion, this report helps the decision makers to allocate the budget they have for the 
expenditures of the health department. It has been proved by the literature and by the 
results from the base-case analysis, that the screening test for Fecal Occult Blood Test is 
cost-effective. However, an effort must be made to sensitize the population, because an 
important factor for the effectiveness of a population-based screening program (FOBT) is 
the participation rate.  
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